Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687453 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine Versus Twice-Daily NPH
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Terminated
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT00687453: Clinical Trial Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
NCT00687453 is a Phase 4 study that was terminated before completion, run by Charles Drew University of Medicine and Science. The registered enrollment target is 27 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00687453, a Phase 4 study, was terminated before completion, sponsored by Charles Drew University of Medicine and Science.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
Interventions
- DRUG Insulin glargine at bedtime instead of NPH
- DRUG NPH twice-daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Why NCT00687453 stopped before completion
NCT00687453 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Insulin glargine at bedtime instead of NPH is the first listed.
NCT00687453 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00687453 about?
NCT00687453 is a clinical study titled "Insulin Glargine Versus Twice-Daily NPH". To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
What is the current status of trial NCT00687453?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2003-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00687453?
The interventions under investigation include: Insulin glargine at bedtime instead of NPH (DRUG), NPH twice-daily (DRUG).
Who is sponsoring clinical trial NCT00687453?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00687453's enrollment target sits among peer trials
27 1651st of 2000 higher than 346 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia